Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Zhitong Finance APP has learned that long-term data from two phase 3 clinical trials by Johnson & Johnson (JNJ.US) show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved clinical remission rates of up to 94% within three years.
According to the report, participants in the GALAXI 2 and GALAXI 3 trials first received Tremfya induction therapy, followed by maintenance therapy of either 100 mg every eight weeks or 200 mg every four weeks. The remission rate was 94% in the eight-week regimen group and 91% in the four-week regimen group.
In addition, 52% of patients in the eight-week regimen group achieved endoscopic remission, compared to 61% in the four-week regimen group.
Meanwhile, 88% of patients in both groups achieved steroid-free clinical remission for 90 days.
Furthermore, Johnson & Johnson stated that results from the phase 3 FUZION study showed that Tremfya achieved sustained fistula remission in certain subgroups of Crohn's disease patients.
Overall, 28% of patients in the eight-week (q8w) regimen group and 27% in the four-week (q4w) regimen group reached the composite endpoint of fistula comprehensive remission at Week 24, compared to 10% in the placebo group.
However, among patients with higher baseline luminal disease activity, the remission rates were 30% for the q8w group and 21% for the q4w group, while the placebo group achieved 0%.
In patients previously treated with biologics, and in patients with or without rectal inflammation at baseline, those treated with Tremfya also had significantly better fistula remission outcomes compared to the placebo group.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tesla (TSLA.US) Takes the First Step Toward Cybercab Popularization: First Invitation for Individual Customers to Purchase
Tesla has invited select customers to purchase the Cybercab, priced at $29,990, with a required monthly subscription fee of $299. The use is limited to personal purposes only, and it is prohibited to operate the vehicle on ride-hailing platforms. Deliveries may begin as early as December.

AirJoule Technologies Q3 2026 net loss more than doubles quarter-on-quarter to $19.8 million
An “important step” in the AI revolution! Anthropic (ANT.US) IPO debuting this week, Ives: A valuation firmly at $1.25 trillion will validate the cloud giants’ capital expenditure logic.
Anthropic will launch its initial public offering (IPO) this week. Yorkville Ives analyst Dan Ives believes that this listing will be an "important step" for the expansion of the AI industry and the broader technology sector.

